Tafenoquine feasibility study in Vietnam

Not Applicable

• Conditions: Malaria plasmodium vivax; Infections and Infestations

• Registration Number: ISRCTN15552312
• Lead Sponsor: PATH

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-12-07
• Last Update Posted: 19 August 2024
• Study Completion: 2025-09-30

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

1. Patient with a confirmed P. vivax infection.
2. Patients providing informed consent or assent

Exclusion Criteria

1. Unwilling to provide informed consent
2. Showing signs of severe infection (patients)

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Measured using patient records at the end of the study:<br>1. Proportion of P. vivax infected individuals that are correctly treated with TQ based on the revised algorithm as an aggregate and within each of three case finding strategies.<br>2. Proportion of P. vivax and mixed P. vivax infected individuals that are correctly treated with PQ based on the revised algorithm as an aggregate and within each of three case finding strategies.